The aim of this study was to compare the duration of spinal anaesthesia in obese and non-obese subjects. We also quantified the effect of body mass index (BMI) on spinal anaesthesia by comparing the median effective dose (ED50) of intrathecal hyperbaric bupivacaine required in the two cohorts. one hundred and eight patients undergoing elective total knee replacement arthroplasty under combined spinal-epidural anaesthesia were enrolled as a non-obese group (BMI <27.5 kg/m 2 ) or obese (o) group (BMI ≥27.5 kg/m 2 ). Each group was further subdivided by bupivacaine doses of 6, 7, 8, 9, 10 or 11 mg, respectively. Anaesthesia was deemed successful if a bilateral T12 sensory block occurred within 15 minutes of intrathecal drug administration and epidural supplementation was not required. The ED50 for successful anaesthesia and that for successful block of tourniquet pain were determined separately by probit regression analysis. Although the analgesic duration was prolonged with higher doses of bupivacaine in group o, the ED50 for successful anaesthesia did not differ between groups. However, the incidence of tourniquet pain was lower in group O and the ED50 for block of tourniquet pain was less in group O. This study suggests that bupivacaine dose reduction is not necessary, but analgesic duration may be prolonged in patients with higher BMI. These patients require careful consideration of spinal anaesthetic dose to minimise the risk of unnecessary prolongation of anaesthesia.
The spread of a drug is unpredictable 1 , but patient factors such as age, gender, height, weight, body mass index (BMI), spinal anatomy and lumbosacral cerebrospinal fluid (CSF) volume are all determinants of sensory block level in subjects undergoing spinal anaesthesia [2] [3] [4] [5] [6] [7] [8] [9] . Among these determinants, the influence of BMI on spinal anaesthesia is controversial and previous studies have reported conflicting results.
Obesity has been reported to be associated with greater cephalad spread of spinal anaesthesia 5, 6 due to a reduced CSF volume caused by extradural vein distention or epidural fat 6 . However, the study which found greater spread in obese patients used isobaric local anaesthetic, which is associated with increased variability in block level 1 . Furthermore, a subsequent study using hyperbaric solution failed to show a significant difference in block height between obese and non-obese patients 3 . Although the degree of cephalad spread may be unchanged, the possibility remains that anaesthetic duration, which was not evaluated in these studies, is prolonged in obese patients. As such, the influence of obesity on spinal anaesthesia is not clear and there is controversy as to whether the dose of spinal anaesthetic should be reduced for obese patients. A shorter duration of spinal anaesthesia than duration of surgery causes anaesthetic failure, but unnecessarily prolonged spinal anaesthesia causes patient discomfort, bladder dysfunction or longer hospital stay. Therefore it is worthwhile determining whether the duration of anaesthesia in obese patients is prolonged compared with nonobese patients.
In this prospective, randomised, double-blind, dose-response study we undertook to determine whether the duration of anaesthesia differed between the obese and non-obese patient, and to compare the median effective dose (ED50) and 90% effective dose (ED90) of intrathecal hyperbaric bupivacaine in obese and non-obese patients, using probit regression analysis.
MATERIALS AnD METHoDS

Design and materials
This study was approved by the Institutional Review Board (SMC-2010-01-14) and all patients provided informed consent. This study was registered at www.clinicaltrials.gov (protocol ID nCT01291186). The patients, of American Society of Anesthesiologists physical status classification I to III, scheduled for total knee replacement arthroplasty (TKRA) during the period January to December 2010, were enrolled in this prospective, randomised, double-blind study. Patients with a history of previous spinal surgery, diabetes or other neuropathy, skin infection at the site of injection, allergy to bupivacaine or other contraindication for spinal anaesthesia were excluded. Patients of height <140 or >160 cm or of BMI <18.5 were also excluded to reduce the effect of height or extreme BMI 10 . According to the Asian obesity criteria issued by a World Health Organization expert panel 10 , in the present study, patients with a BMI of <27.5 kg/m 2 were assigned to the non-obese group (group no, n=54) and those with a BMI of ≥27.5 kg/m 2 were assigned to the obese group (group o, n=54). Patients assigned to these groups were subsequently randomised into six subgroups of nine patients each, based on bupivacaine dose (6, 7, 8, 9, 10, or 11 mg) , using the computer program www.randomizer.org.
Study protocol
no patient received premedication. Standard monitoring was applied, including continuous pulse oximetry and electrocardiography. non-invasive arterial pressure was measured at two-minute intervals from the start of anaesthesia for 20 minutes, and then at five-minute intervals until the end of surgery. All patients were rapidly administered 8 ml/kg of lactated Ringer's solution during the first 10 minutes of spinal anaesthesia, a maintenance dose of 4 ml/kg/hour and 8 ml/kg of colloid (Voluven ® , Fresenius Kabi, Germany) at 6 ml/kg/hour during surgery. oxygen was given at 5 l/minute via a facemask during surgery. A combined spinal-epidural technique at separate levels was performed with the patient in the sitting position. An 18 gauge Tuohy needle (Perican ® , B. Braun Melsungen AG, Germany) was inserted at the L3-4 interspace and an epidural catheter (Perifix ® , B. Braun Melsungen AG, Germany) threaded 2 to 3 cm into the epidural space prior to aspiration for blood or cerebrospinal fluid. no local anaesthetic test dose was administered. Spinal puncture was at the L4-5 interspace using a 25-gauge Whitacre spinal needle (Kimberly-Clarke, Roswell, GA, USA). A freshly prepared solution of hyperbaric bupivacaine (Marcaine Spinal ® , AstraZeneca AB, Sodertalje, Sweden, 5 mg/ml) was injected over 20 seconds. The needle orifice faced cephalad during injection and all patients were then placed in a supine horizontal position. once anaesthesia had been achieved, another anaesthetist, unaware of the bupivacaine dosage, was allowed to enter the operating theatre to manage the patient and to record the relevant study data.
Success of spinal anaesthesia was defined as described by Carvalho and colleagues, with modification 11 . Successful induction was defined as a bilateral T 12 sensory block to pinprick within 15 minutes of intrathecal drug administration. Successful anaesthesia was defined as successful induction with no additional epidural requirement during surgery. Failed anaesthesia was defined as induction failure or a requirement for supplemental epidural analgesia with 2% lignocaine with 1:200,000 adrenaline in 5 ml boluses, repeated as required, to complete surgery, because of either a numerical rating scale where 0 represented "no pain" and 10 represented "worst pain imaginable" pain score ≥2 or the patient's request, irrespective of the attainment of successful induction. Successful block of tourniquet pain was defined as no tourniquet pain reported by the patient during the time of its application, and a failed block of tourniquet pain was recorded if the pain score was ≥2. Subjects with a failed induction were excluded from the analysis of time to patient's first request for supplemental analgesia, time to first self-voiding, or success of tourniquet pain block. In addition, subjects who needed urinary catheterisation were excluded from the time to first self-voiding analysis. Successful anaesthesia or tourniquet pain block were taken as endpoints for calculating the ED50 of spinal bupivacaine.
Measurements
Sensory levels to pinprick were assessed using the following scale 12 : 0=an ability to appreciate a pinprick as sharp; 1=perception of a pinprick as less sharp than in unblocked areas; 2=perception of a pinprick as touch but not sharp (analgesia); and 3=an inability to feel pinprick (anaesthesia). Surgery was allowed to start when the scale was ≥2, assessed at or above T 12 . Sensory changes were recorded bilaterally along the mid-clavicular line by assessing changes in pinprick sensation using a 25-gauge needle, and time to highest level of block was determined.
Motor block in the lower limbs was graded using the Bromage Scale 13 : 0=ability to lift an extended knee at the hip; 1=ability to flex the knee but not to lift an extended leg; 2=ability to flex toes only; and 3=inability to move hip, knees, or toes. Sensory and motor block assessments were performed 2, 5, 10, 15, 20 and 30 minutes after the spinal injection. In all cases except those with failed induction, times to first request for supplemental analgesia were recorded. Patientcontrolled epidural analgesia was not started until a patient requested supplemental analgesia. In each case, onset time and score of tourniquet pain were recorded. Tourniquet pain was not considered to be a failure of anaesthesia.
Hypotension was defined as a decrease in systolic arterial pressure of ≥20% relative to baseline or a mean arterial pressure of <55 mmHg. When hypotension occurred, repeated intravenous ephedrine bolus doses of 5 mg were administered. If the heart rate was <60 beats/minute, atropine (0.5 mg) was administered. nausea and vomiting events were recorded and incidences calculated.
Statistical analysis
For the Cochrane-Armitage test for determining trends in proportions, sample sizes of nine patients per group were required for bupivacaine doses of 6, 7, 8, 9, 10 and 11 mg and proportions of success of 0.5, 0.6, 0.7, 0.8, 0.9 and 0.99. Initial calculations using a two-sided Z-test with continuity correction and a significance level of 0.05 (PASS ® 11.0.2; nCSS, LCC, Kaysville, UT, USA) 14 indicated that a total sample size of 54 subjects was required for a power of 85% to detect a linear trend. Thus, comparison of the ED50 values for obese and non-obese patients required recruitment of 108 subjects.
SPSS software (version 14.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data were analysed using Student's t-test or Mann-Whitney U test depending on the normality of data. Fisher's exact test or chi-square test was used to analyse incidence data. Significance was accepted for P values <0.05. Spearman rank correlation coefficients were calculated to quantify interrelationships between the variables. Using SPSS software, probit regression analysis was performed to obtain the ED50 and ED90 values of bupivacaine for the success of anaesthesia or block of tourniquet pain. Dose-response curves were drawn using Calcusyn software (Version 2.1, BIoSoFT, Cambridge, United Kingdom). The ED50 and ED90 of the two groups were compared using the ED50 ratio test 15 .
RESULTS
All 108 patients enrolled completed the study according to the protocol and were included in the analysis. Demographic and perioperative data were similar between groups except for body weight and BMI ( Table 1 ). The ED50 for successful anaesthesia was 6.9 mg (95% confidence interval [CI] 5.3 to 8.0 mg) in group no and 6.4 mg (95% CI 4.4 to 7.5 mg) in group o. The ED90 of intrathecal hyperbaric bupivacaine was 10.4 mg (95% CI 9.3 to 12.9 mg) in group no and 9.9 mg (95% CI 8.7 to 12.1 mg) in group o. The ED50 and ED90 values did not differ between groups. However, the ED50 or ED90 for block of tourniquet pain were significantly less in group o compared with group no, based on the ED50 ratio test 15 . The ED50 was 6.9 mg (95% CI 6.0 to 7.5 mg) for group no, and 5.5 mg (95% CI 4.2 to 6.3) for group o; the ED90 was 8.5 mg (95% CI 7.9 to 9.8 mg) and 7.2 mg (95% CI 6.4 to 8.3 mg) respectively. Peak sensory block levels, times to peak sensory block level and motor block intensity were similar ( .048) , and the incidence of tourniquet pain was lower in group o (9.3 vs 24.1%, P=0.034). Time to first self-voiding in successful cases was significantly longer in group o (346.9±30.7 vs 322.8±43.6 minutes in group no, P=0.015). no significant inter-group differences were observed with respect to consumption of ephedrine or incidence of hypotension, bradycardia, nausea, vomiting, shivering or pruritus ( Table 3) .
A logistic plot was drawn for anaesthetic success (Figure 1 ) and block of tourniquet pain ( Figure 2 ) for both groups. The duration of analgesia according to the dosage group is shown in Figure 3 . The duration was significantly longer in Group o than Group no in the dose subgroups of 9, 10 and 11 mg (P=0.019, 0.003, 0.001, respectively).
DISCUSSIon
In this study a comprehensive evaluation was performed throughout the course of spinal anaesthesia, whereas previous studies focused on a limited number of time points or on certain aspects of spinal anaesthesia. In the present study the ED50 of intrathecal hyperbaric bupivacaine for successful anaesthesia and the highest levels of sensory and motor blocks did not differ between the two patient cohorts, although time to first request for supplemental analgesia and first self-voiding were significantly prolonged in obese patients. Further, the incidence of tourniquet pain was lower and the ED50 for block of tourniquet pain was significantly less in obese patients.
We expected that the duration of anaesthesia in obese patients would be greater than in nonobese subjects, despite there being no increase in maximum cephalad spread. Indeed the longer times to first request for supplemental analgesia and to first self-voiding suggest that the duration of spinal anaesthesia was prolonged. The mechanism whereby BMI might affect the spread of a spinal block is uncertain, but CSF volume has been postulated to play a major role 8, 9 . It is thought that patient-related characteristics such as age, weight, BMI or height are factors influencing the inter-individual variation in CSF volume. Carpenter and colleagues 8 reported that CSF volume is well correlated with peak sensory block assessed using pinprick and with duration of surgical anaesthesia. Several authors 3, 6, 9, 16, 20, 21 have speculated about the relationship between obesity and distribution of block. If the inferior vena cava is occluded by increased abdominal pressure, blood flow increases through the lumbar vertebral plexus 9 . If the vena cava is compressed more in obese patients due to the weight of abdominal contents and the extradural veins distend, then the volume of CSF may be reduced 3, 6, 13 which in turn could increase the spread of spinal local anaesthetic. If the same amount of local anaesthetic is injected, concentrations in CSF will be higher in those with a lower CSF volume, which could delay clearance and result in a longer effect. Support for this theory comes from a myelographic study 20 which showed that abdominal compression increases the dispersion of a radiopaque material. The same authors also found that an increase in intra-abdominal pressure, achieved by binding the abdomen, increased the cephalad spread of analgesia. Alternatively, it has been proposed that obese patients may have more extradural fat, effectively reducing CSF volume by compressing the dural sac 3, 6 . Endoscopic observations suggest there is no relationship between the amount of extradural and subcutaneous fat 21 .
In the present study, the prolongation of spinal anaesthesia in obese patients was not associated with a significant difference in the ED50 for successful anaesthesia. The probit regression analysis revealed that the ED50 for successful anaesthesia in obese patients did not differ from that in non-obese patients. Carvalho and colleagues 16 performed a dose-ranging study in morbidly obese parturients (BMI ≥40 kg/m 2 ) using similar methodology to this study. They compared the ED50 and ED95 values with those from their previous study in nonobese parturients 17 and concluded that morbidly obese and non-obese patients did not respond differently to 5 to 11 mg of hyperbaric bupivacaine. our findings are consistent with this. A possible explanation is that another factor, such as vertebral column length or CSF volume, is more important than BMI or body weight. In a previous study, vertebral column length was found to be a better correlate with level of sensory anaesthesia than was weight or height 18 . Another theory is that CSF volume is very different among individuals and is not easily predicted by height, weight, or BMI 9 . Therefore, inter-individual variability in CSF volume might have masked inter-group differences. However, many studies support the concept that the CSF volume is reduced in obese subjects 3, 6, 13 . Finally, the difference between the ED50 for successful anaesthesia in the two cohorts may have been masked by the wide confidence intervals. This suggests that although obesity may be associated with a lower CSF volume, the effect is insufficient to decrease the ED50 for that outcome. Meanwhile, the ED50 for block of tourniquet pain was significantly less in obese patients. The spinal anaesthetic level required to block tourniquet pain is higher (L1-2) than that required for successful anaesthesia for TKRA (L3-4). This may explain the different findings between ED50 for successful anaesthesia and block of tourniquet pain.
There was no difference between the groups for peak sensory block. It is possible that hyperbaric local anaesthetic, within the dose range used in this study, spreads cephalad to the most dependent part of the spinal canal, regardless of differences in BMI or CSF volume. The lowest point of the thoracic spinal canal lies at T7-T9 in the supine position 19 and in the present study the highest block level was T7 in both groups.
There was a tendency for the analgesic duration to be significantly prolonged only across higher bupivacaine doses (9, 10, 11 mg). After larger doses of bupivacaine the difference in analgesic duration was greater, perhaps because the smaller CSF volume of obese patients is less influential after low doses of bupivacaine. A critical local anaesthetic dose may exist above which the analgesic duration is significantly prolonged in the obese patient lying supine. However, the mechanism for this is not clear and requires further investigation.
There were more cases of failed anaesthesia in this study than we had anticipated, considering the sensory dermatomes of the knee-joint. An explanation may be the relatively low doses of bupivacaine used as the study evaluated a doseresponse relationship. Second, the sensory block may have regressed during the surgery which lasted more than 100 minutes, such that successful anaesthetic induction failed to predict successful anaesthesia in many cases.
The study has several limitations. First, as there was no subject with a BMI >40 kg/m 2 , representing morbid obesity 22 , the effect of morbid obesity on spinal anesthesia could not be evaluated. However, a study suggests morbidly obese parturients (BMI ≥40 kg/m 2 ) do not differ from normal weight patients in local anesthetic dose requirements 16 . Second, we used a double-space technique for combined spinal-epidural anaesthesia, locating the epidural space prior to spinal anaesthesia performed at a lower intervertebral space. The dura may have been pushed anteriorly and the spread of local anaesthetic impaired by the injection of air at a higher level, influencing the estimation of ED50. Third, we used combined spinal epidural anaesthesia rather than single-shot spinal anaesthesia, so it is possible that attending anaesthetists administered epidural rescue analgesia at relatively low levels of patient discomfort. If so, the estimated ED50 may have been higher than that had spinal anaesthesia been performed. Fourth, the level of injection is often higher than intended in obese patients 23 , and this might increase the duration of spinal anaesthesia. Finally, we used doses of bupivacaine from 6 to 11 mg in both groups, so comparing the spinal anaesthetic characteristics directly between groups might be less clinically relevant. However, this method has usually been used in previous studies that evaluated various effects of different local anaesthetic doses 24, 25 . Therefore in our opinion the results may still be of interest to clinicians.
In conclusion, no difference was found between obese and non-obese subjects regarding the dose of intrathecal hyperbaric bupivacaine required for successful block for TKRA. This suggests the dose of hyperbaric bupivacaine does not need to be reduced for obese patients undergoing TKRA. However, as the analgesic duration and time to self-voiding was prolonged when higher doses of bupivacaine were given to obese patients, these patients need careful consideration of bupivacaine dose to minimise the risk of unnecessary prolongation of anaesthesia.
